|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001815,
umls-concept:C0021764,
umls-concept:C0079189,
umls-concept:C0123759,
umls-concept:C0175630,
umls-concept:C0220901,
umls-concept:C0254610,
umls-concept:C0441889,
umls-concept:C1101536,
umls-concept:C1149197,
umls-concept:C1880156,
umls-concept:C2003903,
umls-concept:C2603343
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2011-3-31
|
|
pubmed:abstractText |
Abnormal cytokine expression accompanies myelofibrosis and might be a therapeutic target for Janus-associated kinase (JAK) inhibitor drugs. This study describes the spectrum of plasma cytokine abnormalities in primary myelofibrosis (PMF) and examines their phenotypic correlates and prognostic significance.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/IL8 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-12,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-15,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-8,
http://linkedlifedata.com/resource/pubmed/chemical/JAK2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Janus Kinase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1356-63
|
|
pubmed:meshHeading |
pubmed-meshheading:21300928-Adult,
pubmed-meshheading:21300928-Aged,
pubmed-meshheading:21300928-Aged, 80 and over,
pubmed-meshheading:21300928-Biopsy,
pubmed-meshheading:21300928-Bone Marrow Examination,
pubmed-meshheading:21300928-Case-Control Studies,
pubmed-meshheading:21300928-Chi-Square Distribution,
pubmed-meshheading:21300928-Cytogenetic Analysis,
pubmed-meshheading:21300928-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:21300928-Female,
pubmed-meshheading:21300928-Genotype,
pubmed-meshheading:21300928-Humans,
pubmed-meshheading:21300928-Interleukin-12,
pubmed-meshheading:21300928-Interleukin-15,
pubmed-meshheading:21300928-Interleukin-8,
pubmed-meshheading:21300928-Janus Kinase 2,
pubmed-meshheading:21300928-Kaplan-Meier Estimate,
pubmed-meshheading:21300928-Male,
pubmed-meshheading:21300928-Middle Aged,
pubmed-meshheading:21300928-Minnesota,
pubmed-meshheading:21300928-Mutation,
pubmed-meshheading:21300928-Phenotype,
pubmed-meshheading:21300928-Predictive Value of Tests,
pubmed-meshheading:21300928-Primary Myelofibrosis,
pubmed-meshheading:21300928-Prognosis,
pubmed-meshheading:21300928-Proportional Hazards Models,
pubmed-meshheading:21300928-Protein Array Analysis,
pubmed-meshheading:21300928-Receptors, Interleukin-2,
pubmed-meshheading:21300928-Risk Assessment,
pubmed-meshheading:21300928-Risk Factors,
pubmed-meshheading:21300928-Tumor Markers, Biological,
pubmed-meshheading:21300928-Up-Regulation
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.
|
|
pubmed:affiliation |
Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. tefferi.ayalew@mayo.edu
|
|
pubmed:publicationType |
Journal Article
|
